Patents by Inventor Yongjin GONG

Yongjin GONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl compounds for kinase inhibition
    Patent number: 11958850
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 16, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Complement Modulators and Related Methods
    Publication number: 20230115176
    Abstract: The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 13, 2023
    Inventors: Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
  • Heteroaryl Compounds For Kinase Inhibition
    Publication number: 20230102829
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 30, 2023
    Inventors: WEI-SHENG HUANG, YONGJIN GONG, FENG LI, NICHOLAS E. BENCIVENGA, DAVID C. DALGARNO, ANNA KOHLMANN, WILLIAM C. SHAKESPEARE, RANNY M. THOMAS, XIAOTIAN ZHU, ANGELA V. WEST, WILLMEN YOUNGSAYE, YUN ZHANG, TIANJUN ZHOU
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20190218212
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 18, 2019
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Heteroaryl compounds for kinase inhibition
    Patent number: 10227342
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 12, 2019
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Heteroaryl compounds for kinase inhibition
    Patent number: 9796712
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 24, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20170253594
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Delgamo, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20170197962
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 13, 2015
    Publication date: July 13, 2017
    Inventors: Wei-Sheng HUANG, Yongjin GONG, Feng LI, Nicholas E. BENCIVENGA, David C. DALGARNO, Anna KOHLMANN, William C. SHAKESPEARE, Ranny M. THOMAS, Xiaotian ZHU, Angela WEST, Willmen YOUNGSAYE, Yun ZHANG, Tianjun ZHOU
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20170166598
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 13, 2015
    Publication date: June 15, 2017
    Inventors: Wei-Sheng HUANG, Feng LI, David C. DALGARNO, Yongjin GONG, Alexey V. ISHCHENKO, Anna KOHLMANN, William C. SHAKESPEARE, Angela V. WEST, Yongjin XU, Willmen YOUNGSAYE, Yun ZHANG, Tianjun ZHOU, Xiaotian ZHU